Scholars@Duke
Derek Nunez

Derek Nunez

Adjunct Professor in the Department of Medicine
Medicine, Endocrinology, Metabolism, and Nutrition

Scholarly Works

Clobetasol Propionate Ophthalmic Suspension to Treat Ocular Inflammation and Pain after Uncomplicated Cataract Surgery.

Journal article Ophthalmology · May 5, 2026 PURPOSE: To evaluate the efficacy and safety of clobetasol propionate ophthalmic suspension (CPN) 0.05% to treat ocular inflammation and pain after cataract surgery. DESIGN: Two multicenter, randomized, double-masked, placebo-controlled phase 3 trials, ide ... Full text Link to item Cite

Dose-selection study of clobetasol propionate ophthalmic suspension that evaluated inflammation and pain after cataract surgery.

Journal article J Cataract Refract Surg · May 1, 2026 PURPOSE: To evaluate clobetasol propionate ophthalmic suspension (CPN) as treatment for inflammation and pain after cataract surgery. SETTING: 9 outpatient surgery centers in the United States. DESIGN: Randomized, double-masked, placebo-controlled, dose-se ... Full text Link to item Cite

GIP mediates the incretin effect and glucose tolerance by dual actions on α cells and β cells.

Journal article Sci Adv · March 2021 Glucose-dependent insulinotropic polypeptide (GIP) communicates nutrient intake from the gut to islets, enabling optimal levels of insulin secretion via the GIP receptor (GIPR) on β cells. The GIPR is also expressed in α cells, and GIP stimulates glucagon ... Full text Link to item Cite

Factors influencing longitudinal changes of circulating liver enzyme concentrations in subjects randomized to placebo in four clinical trials.

Journal article Am J Physiol Gastrointest Liver Physiol · March 1, 2019 Liver enzyme concentrations are measured as safety end points in clinical trials to detect drug-related hepatotoxicity, but little is known about the epidemiology of these biomarkers in subjects without hepatic dysfunction who are enrolled in drug trials. ... Full text Open Access Link to item Cite

Assessment of plasma acylcarnitines before and after weight loss in obese subjects

Journal article Archives of Biochemistry and Biophysics · September 2016 Full text Cite

Glucose and lipid effects of the ileal apical sodium-dependent bile acid transporter inhibitor GSK2330672: double-blind randomized trials with type 2 diabetes subjects taking metformin.

Journal article Diabetes Obes Metab · July 2016 AIMS: To investigate the pharmacodynamics, pharmacokinetics and safety/tolerability of blocking reuptake of bile acids using the inhibitor GSK2330672 (GSK672) in patients with type 2 diabetes (T2D). METHODS: Subjects with T2D taking metformin were enrolled ... Full text Link to item Cite

Therapeutic potential of akeda‐ ‐protein‐receptor‐5 ( ) agonists. ope or hype?

Journal article Diabetes, Obesity and Metabolism · May 2016 The gastrointestinal tract regulates glucose and energy metabolism, and there is increasing recognition that bile acids function as key signalling molecules in these processes. For example, bile acid changes that occur after ba ... Full text Cite

GSK2374697, a long duration glucagon-like peptide-1 (GLP-1) receptor agonist, reduces postprandial circulating endogenous total GLP-1 and peptide YY in healthy subjects.

Journal article Diabetes Obes Metab · October 2015 We investigated the effects of a long-duration glucagon-like peptide-1 (GLP-1) receptor agonist, GSK2374697, on postprandial endogenous total GLP-1 and peptide YY (PYY). Two cohorts of healthy subjects, one normal/overweight and one obese, were randomized ... Full text Link to item Cite

Gut hormone pharmacology of a novel GPR119 agonist (GSK1292263), metformin, and sitagliptin in type 2 diabetes mellitus: results from two randomized studies.

Journal article PLoS One · 2014 UNLABELLED: GPR119 receptor agonists improve glucose metabolism and alter gut hormone profiles in animal models and healthy subjects. We therefore investigated the pharmacology of GSK1292263 (GSK263), a selective GPR119 agonist, in two randomized, placebo- ... Full text Link to item Cite

Safety, Pharmacokinetics, and Pharmacodynamic Effects of a Selective TGR5 Agonist, SB‐756050, in Type 2 Diabetes

Journal article Clinical Pharmacology in Drug Development · July 2013 AbstractTGR5 is a bile acid receptor and a potential target for the treatment of type 2 diabetes (T2D). We report here the safety, pharmacokinetics, and pharmacodynamic effects of a selective TGR5 ago ... Full text Cite

Remogliflozin Etabonate, a Selective Inhibitor of the Sodium-Glucose Transporter 2, Improves Serum Glucose Profiles in Type 1 Diabetes

Journal article Diabetes Care · November 1, 2012 OBJECTIVERemogliflozin etabonate (RE), an inhibitor of the sodium-glucose transporter 2, improves glucose profiles in type 2 diabetes. This study assessed safety, tolerability ... Full text Cite

Assessment of Acute and Chronic Pharmacological Effects on Energy Expenditure and Macronutrient Oxidation in Humans: Responses to Ephedrine

Journal article Journal of Obesity · 2011 Evidence of active brown adipose tissue in human adults suggests that this may become a pharmacological target to induce negative energy balance. We have explored whole-body indirect calorimetry to detect the metabolic effects of thermogenic drugs ... Full text Cite

Multiple‐Dose Pharmacokinetics and Pharmacodynamics of Sergliflozin Etabonate, a Novel Inhibitor of Glucose Reabsorption, in Healthy Overweight and Obese Subjects: A Randomized Double‐Blind Study

Journal article The Journal of Clinical Pharmacology · June 2010 Sergliflozin, the active entity of sergliflozin etabonate, is a selective inhibitor of the sodium‐dependent glucose cotransporter‐2 in the renal tubule. The pharmacokinetics and pharmacodynamics of sergliflozin were examined during administration o ... Full text Cite

Single‐Dose Pharmacokinetics and Pharmacodynamics of Sergliflozin Etabonate, a Novel Inhibitor of Glucose Reabsorption, in Healthy Volunteers and Patients With Type 2 Diabetes Mellitus

Journal article The Journal of Clinical Pharmacology · June 2010 Sergliflozin, the active entity of sergliflozin etabonate, is a selective inhibitor of sodium‐dependent glucose cotransporter 2 (SGLT2). The pharmacokinetics and pharmacodynamics of sergliflozin were evaluated following single oral dose administrat ... Full text Cite

The Biomarkers Consortium: practice and pitfalls of open-source precompetitive collaboration.

Journal article Clin Pharmacol Ther · May 2010 Precompetitive collaboration is a growing driver for innovation and increased productivity in biomedical science and drug development. The Biomarkers Consortium, a public-private platform for precompetitive collaboration specific to biomarkers, demonstrate ... Full text Link to item Cite

Quantitative Magnetic Resonance (QMR) for Longitudinal Evaluation of Body Composition Changes With Two Dietary Regimens

Journal article Obesity · February 2010 We have recently reported a validation study of a prototype low‐field strength quantitative magnetic resonance (QMR) instrument for measurement of human body composition (EchoMRI‐AH). QMR was very precise, but underreported fat mass (FM) by 2–4 kg ... Full text Cite

Validation of a Quantitative Magnetic Resonance Method for Measuring Human Body Composition

Journal article Obesity · January 2008 Objective: To evaluate a novel quantitative magnetic resonance (QMR) methodology (EchoMRI‐AH, Echo Medical Systems) for measurement of whole‐body fat and lean mass in humans.Methods and Procedures: ... Full text Cite

A metabolomic comparison of urinary changes in type 2 diabetes in mouse, rat, and human

Journal article Physiological Genomics · April 2007 Type 2 diabetes mellitus is the result of a combination of impaired insulin secretion with reduced insulin sensitivity of target tissues. There are an estimated 150 million affected individuals worldwide, of whom a large proportion remains undiagn ... Full text Cite

Proton and sodium MRI assessment of fluid level in calf tissue

Journal article Journal of Magnetic Resonance Imaging · July 2006 AbstractPurposeTo investigate the feasibility of using 1H and 23Na MRI to detect fluid levels in the lower leg muscle. Full text Cite

α-Tropomyosin mutations Asp175Asn and Glu180Gly affect cardiac function in transgenic rats in different ways

Journal article American Journal of Physiology-Regulatory, Integrative and Comparative Physiology · September 2004 To study the mechanisms by which missense mutations in α-tropomyosin cause familial hypertrophic cardiomyopathy, we generated transgenic rats overexpressing α-tropomyosin with one of two disease-causing mutations, Asp175Asn or ... Full text Cite

Genetic Determination of Cardiac Mass in Normotensive Rats

Journal article Hypertension · April 1999 Abstract —Genetic determinants affect adult cardiac mass and the predisposition to develop cardiac hypertrophy. The aim of this study was to identify quantitative trait loci (QTL) that control hea ... Full text Cite

Angiotensin II receptor expression and inhibition in the chronically hypoxic rat lung

Journal article British Journal of Pharmacology · November 1996 Full text Cite

Adrenomedullin activity in chronically hypoxic rat lungs

Journal article American Journal of Physiology-Heart and Circulatory Physiology · August 1, 1996 Adrenomedullin (AM) is a novel vasodilator with structural similarities to calcitonin gene-related peptide (CGRP). This study investigated AM activity in the rat lung during hypoxia-induced pulmonary hypertension. Both rat AM (0.2-10 nmol) and alp ... Full text Cite

Hypertensive cardiac hypertrophy—is genetic variance the missing link?

Journal article British Journal of Clinical Pharmacology · July 1996 1Hypertensive cardiac hypertrophy is a major independent predictor of adverse cardiovascular events. In man the cardiac response to increased afterload is very variable, even when ambulatory blood pressure monitoring is used ... Full text Cite

The natriuretic peptide family: turning hormones into drugs

Journal article Journal of Endocrinology · June 1, 1993 IntroductionThe past 10 years have witnessed the discovery of a new peptide family, the natriuretic peptides, which may rival the renin-angiotensin system in their contrib ... Full text Cite

Natriuretic peptide receptor mRNAs in the rat and human heart.

Journal article Journal of Clinical Investigation · November 1, 1992 Full text Cite

Endothelin-1 mRNA expression in the rat kidney

Journal article Biochemical Journal · May 1, 1991 Cultured pig and bovine endothelial cells are capable of synthesizing endothelin-1 (ET-1). Thus the observation that the kidney contains a large number of binding sites for ET distributed in close proximity to endothelial cells suggests that ET-1 m ... Full text Cite

Atrial natriuretic factor mRNA and binding sites in the adrenal gland

Journal article Biochemical Journal · October 15, 1990 The factor inhibiting aldosterone secretion produced by the adrenal medulla may be atrial natriuretic factor (ANF), since the latter abolishes aldosterone release in response to a number of secretagogues, including angiotensin II and K+. In this st ... Full text Cite

Endothelin-1 mRNA is widely expressed in porcine and human tissues.

Journal article Journal of Clinical Investigation · May 1, 1990 Full text Cite

A sensitive radioimmunoassay measuring endothelin-like immunoreactivity in human plasma: Comparison of levels in patients with essential hypertension and normotensive control subjects

Journal article Clinical Science · March 1, 1990 1. A radioimmunoassay has been developed for measuring endothelin-like immunoreactivity in human plasma using an antibody raised against endothelin-1 which also cross-reacts with big endothelin-1 and endothelin-2 but not endothelin-3. ... Full text Cite

A quantitative ‘in-situ’ hybridization method using computer-assisted image analysis. Validation and measurement of atrial-natriuretic-factor mRNA in the rat heart

Journal article Biochemical Journal · October 1, 1989 We have validated a quantitative ‘in-situ’ hybridization method and computer-assisted image analysis of autoradiographs as a technique for measuring atrial-natriuretic-factor (ANF) mRNA in tissue sections of rat heart by: (i) producing radioactive ... Full text Cite

Binding Sites for 125I-Labelled Endothelin-1 in the Kidneys: Differential Distribution in Rat, Pig and Man Demonstrated by Using Quantitative Autoradiography

Journal article Clinical Science · August 1, 1989 1. Quantitative receptor autoradiography in vitro has been used to determine the distribution and density of specific binding sites for 125I-labelled endothelin-1 in human, porcine and rat kidneys. Immunocytochemistry was used to visualize von Will ... Full text Cite